Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.

We are also establishing processes for manufacturing and controls and instituting GMP manufacturing and GLP studies to cater to market needs worldwide. Our lead product out of the platform is EyecyteRPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. We are currently targeting phase-one trials for EyecyteRPE in the later half of 2020.

Recent Scientific Papers

Delighted to announce manufacturing approval from the Indian govt for Eyecyte-RPE to treat Dry age related macular degeneration. We now have a robust, scalable GMP grade protocol which is a huge achievement for team Eyestem.
https://www.linkedin.com/posts/eyestem-research_regenerativemedicine-activity-6720278022240522240-UThP @MacularSociety @Taslimarif

CCAMP startup @EyestemResearch's stemcell therapies restore #vision in early & late stage rat models for retinal degenerative diseases Age-Related Macular Degeneration & Retinitis Pigmentosa
Published in @ARVOinfo's 2020 annual meeting abstract @ARVOiovs
https://iovs.arvojournals.org/article.aspx?articleid=2769526

Career Openings

Junior / Senior Research Fellow

Project: Chemistry, manufacturing and control (CMC) of induced pluripotent stem cells-derived retinal pigment epithelial (RPE) cells for the treatment of age related macular degeneration

View all